Oral treatment of type 2 diabetes mellitus

Česká verzia

Authors: J. Olšovský
Authors place of work: Diabetologické centrum II. interní kliniky Lékařské fakulty MU a FN u sv. Anny Brno, přednosta doc. MUDr. Miroslav Souček, CSc.
Published in the journal: Vnitř Lék 2007; 53(7-8): 853-858
Category:

Summary

The article informs about current views of the ethiopathogenesis of type 2 diabetes mellitus (DM). It presents diabetes as a disease which is chronic and progressive, therefore requiring a dynamic approach to treatment. Based on the above concept, the article lists the current armamentarium of oral antidiabetic drugs and the possibilities of their combining. In addition to the existing therapeutic options, it also brings information about innovative drugs from the above group to be made available in the near future.

Key words:
type 2 diabetes mellitus

Zdroje

1. Butier AE, Janson J, Boner-WeirS et al. Mechanism of reduction of betacell. Diabetes 2003; 52: 102-110.

2. Kahn SE, Hafner SM, Hense MA et al. Glycemic durability of rosiglitazone, metformin or gluburide monotherapy. N Engl J Med 2006; 355: 2427-2443.

3. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in Type 2 diabetes, a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 2006; 49: 1711-1721.

4. Olšovský J. Možnosti ovlivnění inzulinové rezistence. Farmakoterapie 2007; 1: 29-33.

5. Perušičová J et al. Perorální antidiabetika. 1. ed. Praha: Galén 2003.

6. Williams G, Pickup JC (eds). Handbook of Diabetes. 3rd ed. Oxford: Blackwell 2003.

7. www.diab. cz: Standardy: Laboratorní diagnostika a sledování stavu DM.